18:55 , Nov 9, 2018 |  BC Extra  |  Politics & Policy

FDA opens door to new response criteria for cancer immunotherapies

FDA wants to see companies test new immune-specific response endpoints in clinical trials, but first the companies should work with the agency to ensure that bias is minimized and the studies are well controlled. The...
15:53 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Patient sample and rabbit studies suggest estradiol could help treat neurobehavioral disorders associated with defects in interneuron development resulting from preterm birth. In postmortem brain samples from preterm to full-term infants (20-40 gestational...
16:05 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis; multiple sclerosis (MS) Cell culture and mouse studies suggest inhibiting autophagy in T cells could treat juvenile idiopathic arthritis (JIA), MS and other autoimmune diseases. In activated primary CD4 + T cells from...
22:36 , May 8, 2018 |  BC Extra  |  Preclinical News

SNS nerve loss drives hematopoietic stem cell aging

A paper published in...
22:54 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma...
21:14 , Jan 5, 2018 |  BC Week In Review  |  Financial News

Autoimmune company Cue raises $66.2 million IPO

Cancer and autoimmune company Cue Biopharma Inc. (NASDAQ:CUE) raised $66.2 million on Jan. 2 through the sale of 8.8 million shares at $7.50 in an IPO underwritten by MDB Capital Group and Feltl. Spun out...
19:24 , Jan 2, 2018 |  BC Extra  |  Financial News

Cue spikes after pricing $66.2M IPO

Cancer and autoimmune company Cue Biopharma Inc. (NASDAQ:CUE) climbed $4.13 (55%) to $11.63 in its first day of trading Tuesday after raising $66.2 million through the sale of 8.8 million shares at $7.50 in an...
20:54 , Dec 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Organ damage Mouse studies suggest inhibiting CDKN1A could help treat cardiac injury. In cardiac tissue from a neonatal mouse model of surgical resection-induced cardiac injury, levels of CDKN1A were lower in the regenerating myocardium...
19:56 , Nov 17, 2017 |  BC Week In Review  |  Company News

Cue Biopharma in autoimmune deal with Merck

On Nov. 16, Merck & Co. Inc. (NYSE:MRK) partnered with Cue Biopharma Inc. (Cambridge, Mass.) to develop biologics to treat autoimmune diseases. Cue will receive an undisclosed upfront payment, and is eligible for $374 million...
20:23 , Nov 16, 2017 |  BC Extra  |  Company News

Cue Biopharma in autoimmune deal with Merck

Merck & Co. Inc. (NYSE:MRK) partnered with Cue Biopharma Inc. (Cambridge, Mass.) to develop biologics to treat autoimmune diseases. Cue will receive an undisclosed upfront payment, and will be eligible for up to $374 million...